Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Avacta Group plc ( (GB:AVCT) ) has provided an announcement.
Avacta Group plc has completed the sale of its entire issued share capital of Coris Bioconcept SRL to 3B BlackBio Dx Ltd, following the satisfaction of all closing conditions. This strategic move is expected to impact Avacta’s operations by allowing the company to focus more on its core business of developing targeted oncology drugs, potentially strengthening its position in the life sciences industry.
The most recent analyst rating on (GB:AVCT) stock is a Hold with a £47.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.
Spark’s Take on GB:AVCT Stock
According to Spark, TipRanks’ AI Analyst, GB:AVCT is a Neutral.
Avacta Group plc’s overall stock score is influenced primarily by its financial challenges, which weigh heavily despite some positive technical indicators and strategic progress in its oncology focus. The need for additional funding and financial losses are significant concerns, while technical trends provide some short-term optimism.
To see Spark’s full report on GB:AVCT stock, click here.
More about Avacta Group plc
Avacta Group plc is a clinical-stage life sciences company focused on developing innovative, targeted oncology drugs. The company is known for its pre|CISION® platform, a proprietary payload delivery system designed to concentrate highly potent cancer therapies in tumor microenvironments while minimizing impact on normal tissues. Avacta’s pipeline includes pre|CISION® peptide drug conjugates and Affimer® drug conjugates, which offer unique advantages over traditional antibody drug conjugates.
Average Trading Volume: 2,611,129
Technical Sentiment Signal: Buy
Current Market Cap: £246.9M
For detailed information about AVCT stock, go to TipRanks’ Stock Analysis page.